Acyclovir

Generic Name
Acyclovir
Brand Names
Sitavig, Xerese, Zovirax
Drug Type
Small Molecule
Chemical Formula
C8H11N5O3
CAS Number
59277-89-3
Unique Ingredient Identifier
X4HES1O11F
Background

Acyclovir is a nucleotide analog antiviral used to treat herpes simplex, Varicella zoster, herpes zoster, herpes labialis, and acute herpetic keratitis. Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young as 6 years old.

Acyclovir was granted FDA approval on 29 March 1982.

Indication

An acyclovir topical cream is indicated to treat recurrent herpes labialis in immunocompetent patients 12 years and older. Acyclovir oral tablets, capsules, and suspensions are indicated to treat herpes zoster, genital herpes, and chickenpox. An acyclovir topical ointment is indicated to treat initial genital herpes and limited non-life-threatening mucocutan...

Associated Conditions
Bell's Palsy, Chickenpox, Cytomegalovirus (CMV) Infections, Herpes Simplex Infections, Herpes Zoster, Herpes simplex encephalitis, Herpes simplex of the oral-labial, Herpes simplex type I reactivation, Recurrent Genital Herpes (RGH), Recurrent Herpes Labialis, VZV re-activation, Acute Genital herpes, Acute Herpes labialis, Acute Herpetic keratitis, Severe Genital herpes
Associated Therapies
-
Clinical Trials
Related News

Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV

First Posted Date
2007-09-11
Last Posted Date
2018-06-07
Lead Sponsor
University of Washington
Target Recruit Count
28
Registration Number
NCT00527618
Locations
🇺🇸

University of Washington Virology Research Clinic, Seattle, Washington, United States

HSV-2 Shedding Resolution After Acyclovir Treatment

Completed
Conditions
Genital Herpes
Interventions
Drug: acyclovir
First Posted Date
2007-07-03
Last Posted Date
2012-03-22
Lead Sponsor
University of Washington
Target Recruit Count
36
Registration Number
NCT00495573
Locations
🇺🇸

University of Washington Virology Research Clinic, Seattle, Washington, United States

Effect of HSV-2 Suppressive Therapy on Sexual Behavior

Phase 4
Terminated
Conditions
Genital Herpes
Interventions
Drug: acyclovir
First Posted Date
2007-07-03
Last Posted Date
2023-03-07
Lead Sponsor
University of Washington
Target Recruit Count
72
Registration Number
NCT00495716
Locations
🇺🇸

University of Washington Virology Research Clinic, Seattle, Washington, United States

Antimicrobial PK in Infants With Suspected or Confirmed Infection

First Posted Date
2007-06-26
Last Posted Date
2012-11-19
Lead Sponsor
Duke University
Target Recruit Count
450
Registration Number
NCT00491426
Locations
🇺🇸

Children's National Medical Center, Washington, District of Columbia, United States

🇺🇸

University of Texas Southwestern Medical Center, Dallas, Texas, United States

🇺🇸

University of California at San Diego, La Jolla, California, United States

and more 3 locations

Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda

Phase 2
Completed
Conditions
HIV Infections
Herpes Genitalis
Interventions
Drug: Acyclovir
Drug: Placebo
First Posted Date
2006-11-30
Last Posted Date
2012-09-28
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
440
Registration Number
NCT00405821
Locations
🇺🇬

Rakai Health Sciences Program, Uganda Virus Research Institute, Kalisizo, Rakai District, Uganda

Effectiveness of Acyclovir in Suppressing HIV Viral Load in Women Coinfected With HIV and Herpes Simplex Virus Type 2 (HSV-2)

First Posted Date
2006-09-04
Last Posted Date
2013-09-23
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
50
Registration Number
NCT00371592
Locations
🇵🇪

IMPACTA - San Miguel CIPRA Project 1 CRS, San Miguel, Lima, Peru

A Randomized Controlled Trial of Acyclovir Among HIV and HSV-2 Co-Infected Women, Chiang Rai, Thailand

Phase 4
Completed
Conditions
HIV
Herpes
First Posted Date
2006-08-10
Last Posted Date
2006-08-10
Lead Sponsor
Centers for Disease Control and Prevention
Target Recruit Count
67
Registration Number
NCT00362596
Locations
🇹🇭

TUC, Chiang Rai, Thailand

Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2

Phase 4
Completed
Conditions
Genital Herpes
Interventions
Drug: acyclovir
Drug: valacyclovir
First Posted Date
2006-08-09
Last Posted Date
2021-11-18
Lead Sponsor
University of Washington
Target Recruit Count
31
Registration Number
NCT00362297
Locations
🇺🇸

University of Washington Virology Research Clinic, Seattle, Washington, United States

Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT)

First Posted Date
2006-05-25
Last Posted Date
2015-04-21
Lead Sponsor
Hadassah Medical Organization
Target Recruit Count
40
Registration Number
NCT00330018
Locations
🇮🇱

Hadassah Medical Organization,, Jerusalem, Israel

Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant

First Posted Date
2005-09-21
Last Posted Date
2007-12-21
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
120
Registration Number
NCT00209352
Locations
🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy